Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
8Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
ORIC Pharmaceuticals, Inc. (ORIC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
3Distinct source URLs
7High confidence
0.768Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
ORIC Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CONTRACT-MANUFACTURING-ORGANIZATIONS
CONTRACT-MANUFACTURING-ORGANIZATIONS
90%
External expenses include: • the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations (CMOs) and consultants
CONTRACT-RESEARCH-ORGANIZATIONS
CONTRACT-RESEARCH-ORGANIZATIONS
90%
External expenses include: • payments to third parties in connection with the clinical development of our product candidates, including contract research organizations (CROs) and consultants
manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manuf…
Reciprocal relationship from JNJ graph: Reciprocal relationship from ORIC graph: manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product…
Reciprocal relationship from JNJ graph: Reciprocal relationship from ORIC graph: manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product…
manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manuf…
SNYNF
Sanofi
72%
ed in our product candidates as well as product candidates themselves, or retaliatory trade measures taken by China or other countries, which could potentially include restricted access to APIs or st…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ORIC graph: ed in our product candidates as well as product candidates themselves, or retaliatory trade measures taken by China …
AVISTONE-BIOTECHNOLOGY-BEBETTER-MED-SUZHOU-PUHE-
AVISTONE-BIOTECHNOLOGY-BEBETTER-MED-SUZHOU-PUHE-
62%
nufacturer of the diagnostic product is a laboratory. The American Clinical Laboratory Association and a private laboratory have initiated litigation against the agency to challenge the implementatio…
CATALYST-PHARMS-INC
CATALYST-PHARMS-INC
62%
manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manuf…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
tend to commercialize on our own or jointly; • expand our operational, financial and management systems and increase personnel, including personnel to support our development, manufacturing and comme…
JIANGSU-HENGRUI-MEDICINE-CO
JIANGSU-HENGRUI-MEDICINE-CO
62%
nufacturer of the diagnostic product is a laboratory. The American Clinical Laboratory Association and a private laboratory have initiated litigation against the agency to challenge the implementatio…
ORIC Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ORIC-DEBT-11586
Warrants outstanding: 0.0001
90%
xbrl warrant detail from xbrl 2025-05-31.
ORIC-DEBT
Debt stack $10.5M
90%
Market cache reports total debt of $10.5M.
ORIC-DEBT-11587
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
ORIC Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for ORIC Pharmaceuticals, Inc..
ORIC Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
ORIC-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 183 tracked holders.
ORIC Pharmaceuticals, Inc. Extended Supply Chain Network
